- Home
- Publications
- Publication Search
- Publication Details
Title
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-01-09
DOI
10.3389/fphar.2018.01503
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation
- (2018) Xin Yao Qiu et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective study of nivolumab for patients with recurrent high grade gliomas
- (2018) Megan Mantica et al. JOURNAL OF NEURO-ONCOLOGY
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma
- (2018) Drew Pratt et al. NEUROSURGERY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current Challenges and Opportunities in Treating Glioblastoma
- (2018) Andrea Shergalis et al. PHARMACOLOGICAL REVIEWS
- Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
- (2018) Yiting Wang et al. Frontiers in Pharmacology
- Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
- (2018) Chia-Ing Jan et al. Frontiers in Immunology
- The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
- (2018) Joseph DiDomenico et al. OncoImmunology
- PD-1 ( PDCD1 ) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase ( IDH ) Mutations
- (2018) Lea Kristin Röver et al. EBioMedicine
- Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience
- (2018) Cassie Kline et al. JOURNAL OF NEURO-ONCOLOGY
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma
- (2018) Sylvia C. Kurz et al. NEUROLOGY
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation
- (2017) Sheema Almozyan et al. INTERNATIONAL JOURNAL OF CANCER
- Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
- (2017) Song Xue et al. Journal of Hematology & Oncology
- Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome
- (2017) Tsubasa Miyazaki et al. JOURNAL OF NEURO-ONCOLOGY
- Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
- (2017) Kyu Sang Lee et al. JOURNAL OF NEURO-ONCOLOGY
- Correlation of immune phenotype with IDH mutation in diffuse glioma
- (2017) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
- (2017) Joseph P. Antonios et al. NEURO-ONCOLOGY
- Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
- (2017) Tiffany R. Hodges et al. NEURO-ONCOLOGY
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/AkT/MTOR signaling pathway
- (2017) Lei Zhao et al. OncoTargets and Therapy
- A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
- (2017) Paolo D'Arrigo et al. Oncotarget
- Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme
- (2017) Sabrina Heynckes et al. Oncotarget
- Genetic and immune features of resectable malignant brainstem gliomas
- (2017) Yang Zhang et al. Oncotarget
- Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
- (2017) Song Xue et al. Oncotarget
- Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
- (2017) Anna C. Filley et al. Oncotarget
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells
- (2017) Fang Zheng et al. Biomed Research International
- Immune Checkpoint in Glioblastoma: Promising and Challenging
- (2017) Jing Huang et al. Frontiers in Pharmacology
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
- (2017) Samantha N. Reiss et al. Journal for ImmunoTherapy of Cancer
- The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis
- (2017) Song Xue et al. Scientific Reports
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma
- (2016) Matteo Simonelli et al. Immunotherapy
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
- (2016) Deborah T. Blumenthal et al. JOURNAL OF NEURO-ONCOLOGY
- Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti–PD-1 treatment with nivolumab
- (2016) Patrick Roth et al. NEURO-ONCOLOGY
- Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies
- (2016) Sarah T. Garber et al. NEURO-ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- (2016) R. D. Dorand et al. SCIENCE
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
- (2016) T. M. Johanns et al. Cancer Discovery
- Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
- (2016) Jing Zeng et al. Oncotarget
- Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies
- (2016) Joanne Xiu et al. Oncotarget
- PD-1 and its ligands are important immune checkpoints in cancer
- (2016) Yinan Dong et al. Oncotarget
- Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
- (2016) Zheng Wang et al. OncoImmunology
- The Effect of Bone Marrow–Derived Mesenchymal Stem Cell Transplantation on Allodynia and Hyperalgesia in Neuropathic Animals: A Systematic Review with Meta-Analysis
- (2015) Mostafa Hosseini et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- CD4+T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients
- (2015) Daniel Dubinski et al. NEURO-ONCOLOGY
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
- (2015) D. A. Reardon et al. Cancer Immunology Research
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages
- (2013) O. Bloch et al. CLINICAL CANCER RESEARCH
- Myeloid-derived suppressor cells in glioma
- (2013) Masoud Mirghorbani et al. Expert Review of Neurotherapeutics
- PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
- (2013) Y. Liu et al. JOURNAL OF NEUROSCIENCE
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
- (2013) Brian Ahn et al. Cancers
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Survival comparison between glioblastoma multiforme and other incurable cancers
- (2010) B. Tran et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection
- (2010) Elias A Said et al. NATURE MEDICINE
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
- (2008) T. Azuma et al. BLOOD
- B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer
- (2008) Yu Liu et al. CLINICAL IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started